methoxy(4-bromophenylthio)methane | 126714-65-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: methoxy(4-bromophenylthio)methane
• 英文别名: (4-bromophenyl)(methoxymethyl)sulfane；1-bromo-4-(methoxymethylsulfanyl)benzene
• CAS: 126714-65-6
• 化学式: C₈H₉BrOS
• 分子量: 233.129
• InChiKey: ZBXYAAXRAYLIRE-UHFFFAOYSA-N

物化性质

• 沸点：
  260.3±25.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methoxy(4-bromophenylthio)methane 在 水 、 氯 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以95%的产率得到4-溴苯磺酰氯
  参考文献：
  名称：

  A New and Facile Synthesis of Sulfonyl Chlorides

  摘要：

  苯磺酰氯和苄磺酰氯的合成在出色产率下通过芳基（或苄基）甲氧基甲基硫醚的水相氯化反应完成。功能化硫醚可以从溴苯基甲氧基甲基硫醚轻松制备。

  DOI：

  10.1055/s-1992-26333
• 作为产物：
  描述：

  二甲醇缩甲醛 、 4-溴苯硫酚 在 poly(4-vinylpyridine) supported copper(II) oxide nanoparticles 作用下， 以 neat (no solvent) 为溶剂， 反应 0.5h， 生成 methoxy(4-bromophenylthio)methane
  参考文献：
  名称：

  P4VPy–CuO nanoparticles as a novel and reusable catalyst: application at the protection of alcohols, phenols and amines

  摘要：

  采用了超声波辐照法合成了P4VPy–CuO纳米粒子。通过X射线衍射、扫描电子显微镜、透射电子显微镜和傅里叶变换红外光谱对合成的纳米粒子的相关性质进行了研究。在鉴定之后，制备的试剂被用于促进不同类型的醇、酚和胺的保护反应。操作简便、反应时间短、产率高、成本相对较低以及催化剂的重复使用性是所报道方法的显著特点。

  DOI：

  10.1007/s13738-016-0887-x

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] SSAO INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE SSAO ET LEUR UTILISATION
  申请人：ECCOGENE SHANGHAI CO LTD

  公开号：WO2021083209A1

  公开（公告）日：2021-05-06

  Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of formula (I') or (I), and a method of treating or preventing a disease in which SSAO plays a role.

  提供了一个化合物的公式(I')或(I)，其药用盐、水合物、溶剂合物、前药、立体异构体或互变异构体，该化合物调节SSAO的活性，一种包括化合物的药物组合物的公式(I')或(I)，以及一种治疗或预防SSAO在其中发挥作用的疾病的方法。
• BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Santora Vincent J.

  公开号：US20100240653A1

  公开（公告）日：2010-09-23

  The present invention relates to certain biphenyl sulfonamide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3-receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as, cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as narcolepsy, shift-work syndrome, drowsiness as a side effect from a medication, maintenance of vigilance to aid in completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease and the like.

  本发明涉及公式（Ia）的某些联苯磺酰胺衍生物及其制药组合物，其调节组织胺H3受体的活性。本发明的化合物和制药组合物适用于治疗组织胺H3相关疾病的方法，例如认知障碍，癫痫，脑外伤，抑郁症，肥胖症，睡眠和清醒障碍，如嗜睡症，倒班综合征，药物副作用引起的嗜睡，维持警觉以帮助完成任务等，猝倒症，过度睡眠症，嗜睡综合征，时差反应，睡眠呼吸暂停等，注意力缺陷多动障碍（ADHD），精神分裂症，过敏症，上呼吸道过敏反应，过敏性鼻炎，鼻塞，痴呆，阿尔茨海默病等。
• Identification of biaryl sulfone derivatives as antagonists of the histamine H3 receptor: Discovery of (R)-1-(2-(4′-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916)
  作者：Graeme Semple、Vincent J. Santora、Jeffrey M. Smith、Jonathan A. Covel、Rena Hayashi、Charlemagne Gallardo、Jason B. Ibarra、Jeffrey A. Schultz、Douglas M. Park、Scott A. Estrada、Brian J. Hofilena、Brian M. Smith、Albert Ren、Marissa Suarez、John Frazer、Jeffrey E. Edwards、Ryan Hart、Erin K. Hauser、Jodie Lorea、Andrew J. Grottick

  DOI：10.1016/j.bmcl.2011.11.075

  日期：2012.1

  The design of a new clinical candidate histamine-H-3 receptor antagonist for the potential treatment of excessive daytime sleepiness (EDS) is described. Phenethyl-R-2-methylpyrrolidine containing biphenylsulfonamide compounds were modified by replacement of the sulfonamide linkage with a sulfone. One compound from this series, 2j (APD916) increased wakefulness in rodents as measured by polysomnography with a duration of effect consistent with its pharmacokinetic properties. The identification of a suitable salt form of 2j allowed it to be selected for further development. (C) 2011 Elsevier Ltd. All rights reserved.